Page 1062 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

References 9

240. Ramphal R, Kramer BS, Rand KH, Weiner RS, Shands JW, Jr. 255. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of
Early results of a comparative trial of ceftazidime versus recommendations for the use of white blood cell growth fac-
cephalothin, carbenicillin and gentamicin in the treatment of tors: an evidence-based clinical practice guideline. J Clin Oncol.
febrile granulocytopenic patients. J Antimicrob Chemother. 2006;24(19):3187-3205.
1983;12(suppl A):81-88. 256. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recom-
241. Kramer BS, Ramphal R, Rand KH. Randomized comparison mendations for the use of hematopoietic colony-stimulating
between two ceftazidime-containing regimens and cephalothin- factors: evidence-based, clinical practice guidelines. J Clin
gentamicin-carbenicillin in febrile granulocytopenic cancer Oncol. 2000;18(20):3558-3585.
patients. Antimicrob Agents Chemother. 1986;30(1):64-68. 257. Swanson G, Bergstrom K, Stump E, Miyahara T, Herfindal ET.
242. Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Growth factor usage patterns and outcomes in the community
Pizzo PA. Gram-positive infections and the use of vancomycin setting: collection through a practice-based computerized clini-
in 550 episodes of fever and neutropenia. Ann Intern Med. cal information system. J Clin Oncol. 2000;18(8):1764-1770.
January 1988;108(1):30-35.
258. Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ.
243. Viscoli C. Management of infection in cancer patients: stud- Use of hematopoietic colony-stimulating factors: comparison of
ies of the EORTC International Antimicrobial Therapy Group the 1994 and 1997 American Sociaety of Clinical Oncology sur-
(IATG). Eur J Cancer. 2002;38(suppl 4):S82-S87. veys regarding ASCO clinical practice guidelines. J Clin Oncol.
244. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not 1999;17(11):3676-3681.
an essential component of the initial empiric treatment regi- 259. Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoietic
men for febrile neutropenic patients receiving ceftazidime: a colony-stimulating factors: the American Society of Clinical
randomized prospective study. Antimicrob Agents Chemother. Oncology survey. The Health Services Research Committee
1992;36(5):1062-1067. of the American Society of Clinical Oncology. J Clin Oncol.
245. Martino P, Micozzi A, Gentile G, Raccah R, Girmenia C, 1996;14:2511-2520.
Mandelli F. Piperacillin plus amikacin vs. piperacillin plus 260. Bennett CL, Stinson TJ, Tallman MS, et al. Economic analysis
amikacin plus teicoplanin for empirical treatment of febrile epi- of a randomized placebo-controlled phase III study of granu-
sodes in neutropenic patients receiving quinolone prophylaxis. locyte macrophage colony stimulating factor in adult patients
Clin Infect Dis. August 1992;15(2):290-294.
(>55 to 70 years of age) with acute myelogenous leukemia.
246. Kelsey SM, Collins PW, Delord C, Weinhard B, Newland AC. A Eastern Cooperative Oncology Group (E1490). Ann Oncol.
randomized study of teicoplanin plus ciprofloxacin versus gentami- 1999;10(2):177-182.
cin plus piperacillin for the empirical treatment of fever in neutro-
penic patients. Br J Haematol. December 1990;76(suppl 2):10-13. 261. Azoulay E, Delclaux C. Is there a place for granulocyte colony-
stimulating factor in non-neutropenic critically ill patients?
247. Erjavec Z, Vries-Hospers HG, Laseur M, Halie RM, Daenen S. Intensive Care Med. 2004;30(1):10-17.
A prospective, randomized, double-blinded, placebo- controlled
trial of empirical teicoplanin in febrile neutropenia with 262. Paul M, Yahav D, Bivas A, Fraser A, Leibovici L. Anti-
persistent fever after imipenem monotherapy. J Antimicrob pseudomonal beta-lactams for the initial, empirical, treatment
Chemother. 2000;45(6):843-849. of febrile neutropenia: comparison of beta-lactams. Cochrane
248. Wade JC, Glasmacher A. Vancomycin does not benefit persis- Database Syst Rev. 2010;11:CD005197.
tently febrile neutropenic people with cancer. Cancer Treat Rev. 263. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial
2004;30(1):119-126. drug resistance in Greece. Clinical infectious diseases: an offi-
cial publication of the Infectious Diseases Society of America.
249. Paul M, Borok S, Fraser A, Vidal L, Leibovici L. Empirical anti- July 15 2011;53(2):177-184.
biotics against Gram-positive infections for febrile neutropenia:
systematic review and meta-analysis of randomized controlled 264. Samonis G, Koutsounaki E, Karageorgopoulos DE, et al.
trials. J Antimicrob Chemother. 2005;55(4):436-444. Empirical therapy with ceftazidime combined with levofloxacin
or once-daily amikacin for febrile neutropenia in patients with
250. Feld R. Vancomycin as part of initial empirical antibiotic
therapy for febrile neutropenia in patients with cancer: pros and neoplasia: a prospective comparative study. Eur J Clin Microbiol
cons. Clin Infect Dis. 1999;29(3):503-507. Infect Dis. July 2012;31(7):1389-1398.
251. Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, 265. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy
Mengoli C. Reappraisal with meta-analysis of the addition of for Klebsiella pneumoniae bacteremia: implications of produc-
Gram-positive prophylaxis to fluoroquinolone in neutropenic tion of extended-spectrum beta-lactamases. Clin Infect Dis. July
patients. J Clin Oncol. 2003;21(22):4127-4137. 1, 2004;39(1):31-37.
252. Forrest GN, Schimpff SC, Cross A. Febrile neutropenia, colony- 266. Bow EJ. Neutropenic fever syndromes in patients undergoing
stimulating factors and therapy: time for a new methodology? cytotoxic therapy for acute leukemia and myelodysplastic syn-
Support Care Cancer. 2002;10(3):177-180. dromes. Semin Hematol. July 2009;46(3):259-268.
253. Bouchama A, Khan B, Djazmati W, Shukri K. Hematopoietic 267. Serra P, Santini C, Venditti M, Mandelli F, Martino P.
colony-stimulating factors for neutropenic patients in the ICU. Superinfections during antimicrobial treatment with beta-
Intensive Care Med. September 1999;25(9):1003-1005. lactam-aminoglycoside combinations in neutropenic
254. Berghmans T, Paesmans M, Lafitte JJ, et al. Therapeutic use of patients with hematologic malignancies. Infection. 1985;
granulocyte and granulocyte-macrophage colony-stimulating 13(suppl 1):S115-S122.
factors in febrile neutropenic cancer patients: a systematic 268. Nucci M, Spector N, Bueno AP, et al. Risk factors and attribut-
review of the literature with meta-analysis. Support Care Cancer. able mortality associated with superinfections in neutropenic
2002;10(3):181-188. patients with cancer. Clin Infect Dis. 1997;24(4):575-579.

Section05-O-ref.indd 9 1/20/2015 4:51:20 PM